Onconova Gets up to $565M in Phase III MDS Baxter Deal

Onconova Therapeutics Inc.'s deal with Baxter International Inc. for European rights to rigosertib for myelodysplastic syndromes (MDS) and pancreatic cancer, worth up to $565 million, tops off a string of agreements over the past few years that leaves the company with full U.S. ownership of the late-stage compound.